Space Exploration Technologies Corp.
SpaceX became the Fund's dominant contributor after completing its public offering, and Baron remains extremely positive on its long-term prospects. The IPO raised more than $85…
Baron Asset Fund is a mid-cap growth fund that typically owns competitively advantaged businesses for long periods and can establish significant positions where the manager has the greatest conviction. Its portfolio combines secular growth companies across technology, communication services, industrials, financials and healthcare, with SpaceX representing an unusually large position at quarter end.
SpaceX became the Fund's dominant contributor after completing its public offering, and Baron remains extremely positive on its long-term prospects. The IPO raised more than $85…
Amphenol's shares recovered after previously selling off on concerns that copper interconnect products could eventually be displaced by optical technologies. Baron believes…
Quanta provides infrastructure solutions across electric and gas utilities, renewable energy, communications, pipelines and other energy markets. Shares benefited from enthusiasm…
Arch underperformed as investors rotated away from resilient insurance stocks and property insurance pricing softened. Baron views this pricing cyclicality as normal rather than…
CoStar's shares fell as fears about AI disruption caused significant multiple compression despite little evidence of a fundamental impact on the business. Baron continues to own…
Guidewire declined after several new sales moved from the fiscal third quarter into the fourth quarter, which Baron views as a timing issue because those deals subsequently…
Gartner detracted as increasing fears about AI disruption caused its valuation multiple to compress. Baron continues to own the company because of its large addressable market…
Baron initiated Cerebras following its IPO because it believes the company has developed one of the most differentiated architectures for fast AI inference. Demand for tokens per…
Baron initiated Edwards Lifesciences because of its leadership in transcatheter aortic valve replacement and its emerging mitral and tricuspid valve therapies. The team believes…
Source PDFs are not republished here; only extracted ideas and quotes.